- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Hillevax director Aditya Kohli sells shares worth over $985 million | 2 | Investing.com | ||
| 20.03. | Recap: HilleVax Q4 Earnings | 4 | Benzinga.com | ||
| 20.03. | HilleVax files $500M mixed securities shelf | 2 | Seeking Alpha | ||
| 20.03. | HilleVax GAAP EPS of -$0.78 beats by $0.05 | 1 | Seeking Alpha | ||
| 20.03. | HilleVax, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.03. | HilleVax, Inc.: HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress | 47 | GlobeNewswire (Europe) | Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable... ► Artikel lesen | |
| 20.03. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | HilleVax, Inc.: HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference | 1 | GlobeNewswire (USA) | ||
| 18.01. | HilleVax Appoints GSK's Sean McLoughlin As COO | 3 | RTTNews | ||
| 18.01. | HilleVax appoints McLoughlin as COO | 1 | Seeking Alpha | ||
| 18.01. | HilleVax, Inc.: HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer | 321 | GlobeNewswire (Europe) | BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment... ► Artikel lesen | |
| 18.01. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.01. | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.01. | HilleVax, Inc.: HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 08.12.23 | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.23 | HilleVax GAAP EPS of -$0.81 beats by $0.03 | 1 | Seeking Alpha | ||
| 09.11.23 | HilleVax, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.11.23 | HilleVax, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08.23 | HilleVax, Inc.: HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress | 403 | GlobeNewswire (Europe) | BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial... ► Artikel lesen | |
| 12.05.23 | HilleVax, Inc.: HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress | 484 | GlobeNewswire (Europe) | BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -3,11 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,095 | +2,34 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,862 | 0,00 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,710 | +4,46 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 1,080 | +0,93 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ARCTURUS THERAPEUTICS | 26,520 | -4,98 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,010 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 9,430 | +1,23 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,030 | +0,33 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,195 | +5,21 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,460 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,590 | -6,16 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,920 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen HILLEVAX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,39 % bei einem Aktienkurs von 14,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
